Michael S. Weiss - 08 Jan 2026 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Reporting relationship: CEO, Director
Issuer ticker: TGTX
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 17:16:39 UTC
Prior SEC filing: 07 Nov 2025
Next SEC filing: 20 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael S. Weiss

Key filing fact

Michael S. Weiss filed Form 4 for TG THERAPEUTICS, INC. (TGTX) on 09 Jan 2026.

Key facts

This page summarizes Michael S. Weiss's Form 4 filing for TG THERAPEUTICS, INC. (TGTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jan 2026, 17:16.

Change

Previous filing in this sequence was filed on 07 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001038977 Primary reporting owner

WEISS MICHAEL S

Relationship: CEO, Director
Address: 3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE
Signature: /s/ Michael S. Weiss
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TGTX transaction

Common Stock

Award

Transaction value: $0
Shares: +622,000
Change %: +6.8%
Price: $0.000000
Shares after: 9,778,086
Date: 08 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.

Footnote F2

Includes shares of restricted Common Stock, which vest over various time periods.